The GLP-1 receptor agonist class has transformed metabolic research over the past five years. What began with single-receptor GLP-1 agonists has evolved into dual and now triple-receptor agents that produce weight loss approaching bariatric surgery territory. For researchers designing protocols, choosing between Semaglutide, Tirzepatide, and Retatrutide requires understanding their molecular differences, not just their brand names.
This guide compares all three compounds head-to-head using real molecular data, clinical trial outcomes, and practical considerations for research use.
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Molecular Formula | C187H291N45O59 | C225H348N48O68 | C221H343N47O67 (approx.) |
| Molecular Weight | 4,113.58 g/mol | 4,813.53 g/mol | ~4,725.3 g/mol |
| Half-Life | ~165 hours (7 days) | ~117 hours (5 days) | ~144 hours (6 days) |
| Receptor Targets | GLP-1 receptor | GIP receptor + GLP-1 receptor | GIP receptor + GLP-1 receptor + Glucagon receptor (GCGR) |
| Mechanism | Single agonist | Dual co-agonist | Triple co-agonist |
| Dosing Frequency | Once weekly | Once weekly | Once weekly |
| Maximum Trial Weight Loss | ~14.9% (STEP 1, 68 weeks) | ~22.5% (SURMOUNT-1, 72 weeks, 15 mg) | ~24.2% (Phase 2, 48 weeks, 12 mg) |
| FDA Approval (Obesity) | June 2021 (Wegovy) | November 2023 (Zepbound) | Not yet approved (Phase 3 ongoing) |
| Research Product | Semaglutide → | Tirzepatide → | Retatrutide → |
Semaglutide (molecular weight 4,113.58 g/mol, formula C187H291N45O59) is a 31-amino-acid peptide analog of human GLP-1 with two key modifications: an aminoisobutyric acid (Aib) substitution at position 8 that confers DPP-4 resistance, and a C18 fatty diacid chain attached via a hydrophilic spacer to lysine at position 26, which enables strong but reversible albumin binding. That albumin binding is what stretches the half-life to 165 hours, making once-weekly dosing possible.
As a pure GLP-1 receptor agonist, Semaglutide works through a single pathway: it activates GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppresses glucagon release from alpha cells, and slows gastric emptying. Centrally, it acts on GLP-1 receptors in the arcuate nucleus of the hypothalamus and the area postrema to reduce appetite and increase satiety.
Key clinical data (STEP 1 trial, New England Journal of Medicine, 2021): At 68 weeks, participants on 2.4 mg weekly Semaglutide lost an average of 14.9% of baseline body weight versus 2.4% for placebo. This study (n=1,961) established Semaglutide as the benchmark against which all subsequent incretin-based weight loss agents are measured.
Best for: Researchers who need a well-characterized single-receptor agonist with the longest clinical track record (over 25,000 patient-years of exposure data across the SUSTAIN and STEP programs) and the most predictable side-effect profile.
Tirzepatide (molecular weight 4,813.53 g/mol, formula C225H348N48O68) is a 39-amino-acid linear peptide engineered as a dual GIP/GLP-1 receptor co-agonist. Structurally, it is based on the GIP sequence backbone with GLP-1-like substitutions, a C20 fatty diacid chain at lysine-20 for albumin binding (giving it a half-life of 117 hours), and Aib substitutions for DPP-4 stability.
The innovation with Tirzepatide is GIP receptor agonism. GIP (glucose-dependent insulinotropic polypeptide) was historically dismissed as a weight-loss target because GIP receptor knockout mice resist diet-induced obesity, suggesting GIP antagonism, not agonism, would reduce weight. But Tirzepatide proved the opposite: GIP agonism, when paired with GLP-1 agonism, amplifies weight loss beyond what either receptor alone can achieve. GIP appears to reduce the nausea and GI side effects of GLP-1 agonism while adding complementary effects on adipose tissue insulin sensitivity.
Key clinical data (SURMOUNT-1 trial, NEJM, 2022): At 72 weeks, the 15 mg Tirzepatide group (n=630) lost an average of 22.5% of body weight compared to 2.4% for placebo. This was the first obesity pharmacotherapy trial to break the 20% average weight loss threshold, putting Tirzepatide in a class by itself at the time. The 10 mg group lost 21.4% and the 5 mg group lost 16.0%.
Best for: Researchers seeking maximum weight loss among currently approved agents, or those studying how combined GIP/GLP-1 receptor activation alters energy expenditure and substrate utilization beyond what GLP-1 agonism alone achieves.
Retatrutide (LY3437943, molecular weight approximately 4,725.3 g/mol) is a 39-amino-acid peptide designed to activate three receptors simultaneously: GIP, GLP-1, and the glucagon receptor (GCGR). This triple-agonist approach targets three pillars of energy balance — appetite suppression (GLP-1), improved insulin sensitivity and adipose function (GIP), and increased energy expenditure (glucagon).
The addition of glucagon receptor agonism is the wildcard. Glucagon increases hepatic glucose output (which sounds counterproductive for metabolic health) but it also increases resting energy expenditure and promotes lipolysis and fatty acid oxidation. In Retatrutide, the GLP-1 component suppresses the hyperglycemic effect of glucagon agonism while preserving the thermogenic benefit, a balancing act fine-tuned through extensive SAR optimization.
Key clinical data (Phase 2, NEJM, 2023): At 48 weeks, the 12 mg Retatrutide group lost 24.2% of body weight, with approximately 26% of participants losing ≥30% of baseline weight. The 8 mg group lost 22.0% and the 4 mg group lost 17.0%. These results are remarkable for a Phase 2 trial and explain why Eli Lilly advanced Retatrutide directly into the Phase 3 TRIUMPH program (expected completion 2025-2026).
Best for: Cutting-edge research protocols investigating the metabolic effects of glucagon receptor agonism in combination with incretin signaling, or studies where the highest possible weight loss is the primary endpoint. Note that Retatrutide is not yet FDA-approved; it is available for research purposes only.
| Weeks on Treatment | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 15 mg (SURMOUNT-1) | Retatrutide 12 mg (Phase 2) |
|---|---|---|---|
| Week 12 | ~6% | ~8% | ~9% |
| Week 24 | ~10% | ~15% | ~16% |
| Week 48 | ~14% | ~20% | ~24.2% |
| Week 68-72 | ~14.9% | ~22.5% | Data pending (Phase 3) |
Note: These percentages come from different trials with different populations and protocols, so cross-trial comparisons must be interpreted cautiously. A true head-to-head trial (SURMOUNT-5, Tirzepatide vs Semaglutide) is underway, and the TRIUMPH program will provide direct Retatrutide comparisons.
All three compounds share a similar gastrointestinal AE profile rooted in GLP-1 receptor agonism: nausea (20-45% across trials), vomiting (8-20%), diarrhea (15-30%), and constipation (10-25%). These side effects are dose-dependent and usually attenuate after 4-8 weeks as GI adaptation occurs. Key differences:
Semaglutide remains the reference standard: the most studied, the most widely prescribed, and the only GLP-1 agonist with proven cardiovascular outcomes benefit from a dedicated outcomes trial. Tirzepatide raises the efficacy ceiling to ~22.5% weight loss via dual agonism, making it the strongest currently approved option. Retatrutide pushes toward 25% weight loss by adding glucagon receptor activation and may redefine what pharmacotherapy for obesity can achieve — once Phase 3 data confirms the Phase 2 signal.
No single GLP-1 agonist is "best" in absolute terms. The right choice depends on your research question, your endpoints, and whether you need a pure single-receptor tool, a dual agonist for superior weight loss, or a triple agonist at the bleeding edge of metabolic pharmacology.
Browse our complete GLP-1 research peptide catalog: Semaglutide • Tirzepatide • Retatrutide
For proper handling and storage of these peptides, read our peptide storage guide.